Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a
25%-50% of patients treated with several commonly used anti-cancer drugs including
capecitabine and sunitinib. These drugs are known to improve survival in many cancers,
including cancers of the colon, stomach, liver, breast, kidney, and GI stromal tumors (GIST).
Worldwide, over 400,000 patients per year are treated with one of these agents. HFS involves
skin changes, such as swelling, peeling, and blistering of the palms and soles, which is
often painful and debilitating. As a result, HFS-related symptoms can frequently lead to dose
reduction and/or discontinuation of otherwise effective anti-cancer treatment. There is no
treatment for HFS other than dose reduction or stopping treatment. This proposal could
quickly lead to treatments to prevent and/or treat HFS and help patients avoid debilitating
side effects while continuing otherwise effective treatments for their cancer.